Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1PWX2)

• Drug Name: Grassystatin a Drug Info
• Synonyms: Grassystatin A; CHEMBL567893; GTPL8674

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44255320
  TTD Drug ID: DM1PWX2

Molecule-Related Drug Atlas

Drug(s) Targeting Tryptase alpha/beta-1 (Tryptase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[3]
Lactoferrin	DMA7QTC	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
APC-2059	DM8IB6K	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[4]
APC-366	DM02DNQ	Asthma	CA23	Discontinued in Phase 2	[3]
BABIM	DM8AGOE	Asthma	CA23	Terminated	[3]
BAY-17-1998	DM7LZFQ	Asthma	CA23	Terminated	[5]
BAY-44-3428	DM40ORU	Asthma	CA23	Terminated	[6]
BMS-262084	DMETNA3	Discovery agent	N.A.	Investigative	[7]
AMG-126737	DM9H7AZ	Discovery agent	N.A.	Investigative	[8]
MOL 6131	DMSF8UC	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Pancreatic elastase 1 (CELA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[9]
Erdosteine	DM6QFSV	Bronchitis	CA20	Approved	[10]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[11]
Mdl 101,146	DMRSOBG	Inflammation	1A00-CA43.1	Terminated	[12]
WIN-63759	DMRV48P	Emphysema	CA21	Terminated	[13]
SSR-69071	DMWL4MI	Chronic obstructive pulmonary disease	CA22	Terminated	[14]
SYN-1134	DMG2SQM	Cystic fibrosis	CA25	Terminated	[15]
PBI-1101	DMWD1RC	Inflammation	1A00-CA43.1	Terminated	[16]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[12]
Dimethylformamide	DML6O4N	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Cationic trypsinogen (PRSS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[18]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[19]
Ulinastatin	DMIQCFG	Premature labour	JB00	Phase 3	[20]
Alpha-1 antitrypsin	DM5EFXZ	Coagulation defect	3B10.0	Phase 2	[21]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[22]
RWJ-56423	DM6BIHE	Asthma	CA23	Discontinued in Phase 1	[23]
Patamostat	DM6HBQJ	Hypotension	BA20-BA21	Terminated	[21]
BMY-44621	DM8R3N0	N. A.	N. A.	Terminated	[24]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[25]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	DME3PUT	Discovery agent	N.A.	Investigative	[26]

Drug(s) Targeting Cathepsin D (CTSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID10498202C1	DMXE0F2	Multiple sclerosis	8A40	Clinical trial	[27]
CI-992	DMBHYIJ	Hypertension	BA00-BA04	Terminated	[28]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[12]
PMID8410973C3	DM6J5KY	Discovery agent	N.A.	Investigative	[29]
KNI-10006	DMMISH6	Discovery agent	N.A.	Investigative	[30]
GRL-7234	DMR93MK	Discovery agent	N.A.	Investigative	[31]
S-Methylcysteine	DMAMRKS	Discovery agent	N.A.	Investigative	[12]
Carbocyclic Peptidomimetic	DM87SOX	Discovery agent	N.A.	Investigative	[32]
N-Aminoethylmorpholine	DMWXBYC	Discovery agent	N.A.	Investigative	[12]
1h-Benoximidazole-2-Carboxylic Acid	DMNZAVE	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[33]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[34]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[35]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[36]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[37]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[37]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[38]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[39]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[19]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[40]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Caspase-11 (CASP11)	TT6KIOT	CASP4_HUMAN	Inhibitor	[2]
Cathepsin D (CTSD)	TTPT2QI	CATD_HUMAN	Inhibitor	[2]
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Inhibitor	[2]
Pancreatic elastase 1 (CELA1)	TT3NKIB	CELA1_HUMAN	Inhibitor	[2]
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Inhibitor	[2]
Tryptase alpha/beta-1 (Tryptase)	TTM1TDX	TRYB1_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8674).
• [2] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [3] Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
• [4] Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13.
• [5] Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
• [6] Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
• [7] Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.
• [8] Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000.
• [9] Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [11] Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
• [12] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [13] Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Development Research Volume 34, Issue 3, pages 306-316, March 1995.
• [14] Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem. 2011 Aug 19;286(33):28889-901.
• [15] EP patent application no. 1292314, Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans.
• [16] CN patent application no. 1813706, Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage.
• [17] Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6.
• [18] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [19] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [20] Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
• [21] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [22] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [23] Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
• [24] Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
• [25] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [26] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
• [27] Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
• [28] Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
• [29] Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
• [30] alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
• [31] Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
• [32] Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.
• [33] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [34] The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
• [35] Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
• [36] Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
• [37] Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
• [38] Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
• [39] Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
• [40] Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.